KR910016318A - 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물 - Google Patents

이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물 Download PDF

Info

Publication number
KR910016318A
KR910016318A KR1019910004167A KR910004167A KR910016318A KR 910016318 A KR910016318 A KR 910016318A KR 1019910004167 A KR1019910004167 A KR 1019910004167A KR 910004167 A KR910004167 A KR 910004167A KR 910016318 A KR910016318 A KR 910016318A
Authority
KR
South Korea
Prior art keywords
active agent
increasing
composition used
concentration
ion electrophoresis
Prior art date
Application number
KR1019910004167A
Other languages
English (en)
Other versions
KR930005320B1 (ko
Inventor
에이치. 세이지 쥬니어 버튼
이. 리비에르 제임스
Original Assignee
알. 피. 오을물러
벡톤, 디킨슨 앤드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알. 피. 오을물러, 벡톤, 디킨슨 앤드 컴퍼니 filed Critical 알. 피. 오을물러
Publication of KR910016318A publication Critical patent/KR910016318A/ko
Application granted granted Critical
Publication of KR930005320B1 publication Critical patent/KR930005320B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피부 혈관계의 상부 모세관계재(10), 상부 모세관계재에 연결된 심부 혈관 및 심부 혈관을 연결하는 측 혈관(14)을 나타내는 피부(10)의 단면도이다. 제2도는 활성제의 침투력(심도)을 증대시키는 혈관수축제의 농력을 나타내는 각 인자를 Pareto 차트(chart)로 표시한 것이다. 제3도는 활성제의 효력 지속시간(시간)을 증대시키는 혈관수축제의 능력을 나타내는 각 인자를 Pareto차트로 표시한 것이다.

Claims (2)

  1. 피부내 농도를 증가시키는 양의 혈관수축제 및 활성제를 포함하며 이온 전기 도입법으로 딜리버리시키는데 사용되는 제약학적으로 허용가능한 조성물.
  2. (a)피부내 농도를 증가시키는 양의 혈관수축제를 활성제에 부가하고 (b)이온 전기 도입법으로 (a)의 제약학적으로 허용가능한 조성물을 딜리버리시키는 것으로 구성되는, 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910004167A 1990-03-15 1991-03-15 이온전기도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물 KR930005320B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49406290A 1990-03-15 1990-03-15
US494,062 1990-03-15
US07/653,204 US5334138A (en) 1990-03-15 1991-02-08 Method and composition for increased skin concentration of active agents by iontophoresis
US653,204 1991-02-09

Publications (2)

Publication Number Publication Date
KR910016318A true KR910016318A (ko) 1991-11-05
KR930005320B1 KR930005320B1 (ko) 1993-06-17

Family

ID=23962871

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019910004166A KR930005319B1 (ko) 1990-03-15 1991-03-15 이온전기도입에 의한 딜리버리를 증가시키는 방법 및 여기에 사용되는 조성물
KR1019910004165A KR910016316A (ko) 1990-03-15 1991-03-15 공이온전기도입법 및 공이온전기도입용 조성물
KR1019910004167A KR930005320B1 (ko) 1990-03-15 1991-03-15 이온전기도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1019910004166A KR930005319B1 (ko) 1990-03-15 1991-03-15 이온전기도입에 의한 딜리버리를 증가시키는 방법 및 여기에 사용되는 조성물
KR1019910004165A KR910016316A (ko) 1990-03-15 1991-03-15 공이온전기도입법 및 공이온전기도입용 조성물

Country Status (10)

Country Link
US (2) US5334138A (ko)
EP (1) EP0448300A3 (ko)
JP (1) JPH07103046B2 (ko)
KR (3) KR930005319B1 (ko)
AU (1) AU7270091A (ko)
CA (1) CA2038097C (ko)
FI (1) FI911267A (ko)
IE (1) IE910714A1 (ko)
NO (1) NO911020L (ko)
ZA (2) ZA911875B (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64891B1 (en) * 1990-03-15 1995-09-20 Becton Dickinson Co Composition for increased skin concentration of active agents by iontophoresis
US6004309A (en) 1990-03-30 1999-12-21 Alza Corporation Method and apparatus for controlled environment electrotransport
US5125894A (en) * 1990-03-30 1992-06-30 Alza Corporation Method and apparatus for controlled environment electrotransport
US6287484B1 (en) 1992-11-12 2001-09-11 Robert Hausslein Iontophoretic material
US6060000A (en) * 1992-11-12 2000-05-09 Implemed, Inc. Iontophoretic material containing carbon and metal granules
AU681390B2 (en) * 1993-04-08 1997-08-28 University Of Queensland, The Administration of vaso-active agent and therapeutic agent
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US6377847B1 (en) * 1993-09-30 2002-04-23 Vyteris, Inc. Iontophoretic drug delivery device and reservoir and method of making same
US20050159698A1 (en) * 1993-09-30 2005-07-21 Vyteris, Inc. Iontophoretic drug delivery device and reservoir and method of making same
JP3549540B2 (ja) * 1994-03-30 2004-08-04 アルザ・コーポレーション 電気的移送式投与中の皮膚刺激状態の軽減
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US5788666A (en) * 1995-06-15 1998-08-04 Empi, Inc. Iontophoresis electrode
US5840056A (en) * 1995-06-15 1998-11-24 Empi, Inc. Iontophoresis electrode
US5833647A (en) * 1995-10-10 1998-11-10 The Penn State Research Foundation Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery
WO1997038648A1 (en) * 1996-04-16 1997-10-23 Implemed, Inc. Iontophoretic material
US5759564A (en) * 1996-04-16 1998-06-02 Implemed, Inc. Iontophoretic material
AU3404097A (en) * 1996-06-19 1998-01-07 Becton Dickinson & Company Iontophoretic delivery of cell adhesion inhibitors
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6246904B1 (en) 1996-12-17 2001-06-12 Alza Corporation Electrotransport drug delivery reservoirs containing inert fillers
US6650934B2 (en) 1996-12-17 2003-11-18 Alza Corp Polymeric foam reservoirs for an electrotransport delivery device
US6119036A (en) 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5954675A (en) * 1997-07-07 1999-09-21 Dellagatta; Enrico Michael Method of ultrasonic therapy
WO1999018797A1 (en) 1997-10-09 1999-04-22 Emory University Method and devices for transdermal delivery of lithium
US6295469B1 (en) 1997-11-14 2001-09-25 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
US6319901B1 (en) * 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6560483B1 (en) * 2000-10-18 2003-05-06 Minnesota High-Tech Resources, Llc Iontophoretic delivery patch
US6553255B1 (en) 2000-10-27 2003-04-22 Aciont Inc. Use of background electrolytes to minimize flux variability during iontophoresis
US20030065285A1 (en) * 2001-07-23 2003-04-03 Higuchi William I. Method and apparatus for increasing flux during reverse iontophoresis
US20030092774A1 (en) * 2001-10-17 2003-05-15 Parkinson Thomas M. Methods for treating neoplastic, angiogenic, vascular, fibroblastic, and/or immunosuppressive iregularities of the eye and/or joint via administration of combretastatin based medicaments, and iontophoretic devices for delivering combretastatin based medicaments
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US20060062836A1 (en) * 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
JP2006296511A (ja) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc 外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ
US20070078372A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Iontophoresis Drug Delivery Formulation Providing Acceptable Sensation and Dermal Anesthesia
US20070078434A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
JP2009509659A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 生体界面への活性物質の送達のイオントフォレーシス装置及び方法
WO2007041323A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of vesicle-encapsulated active agents
WO2007041158A1 (en) * 2005-09-30 2007-04-12 Vyteris, Inc. Iontophoresis drug delivery device providing acceptable depth and duration of dermal anesthesia
WO2007041322A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
US20070078373A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
EP1931417A2 (en) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
WO2007046103A2 (en) * 2005-10-19 2007-04-26 Perf-Action Technologies Ltd. System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof
WO2007079193A2 (en) * 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
WO2008087803A1 (ja) * 2007-01-16 2008-07-24 Hokkaido University 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
MX2009012273A (es) * 2007-05-18 2010-04-09 Tti Ellebeau Inc Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
ES2454974T3 (es) 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
AR073575A1 (es) * 2008-09-10 2010-11-17 Transcu Ltd Aparato y metodo para dispensar basados en hpc liquidos viscosos en sustratos porosos por ejemplo proceso continuo basado en bandas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991755A (en) * 1973-07-27 1976-11-16 Medicon, Inc. Iontophoresis apparatus for applying local anesthetics
US4406658A (en) * 1981-03-06 1983-09-27 Medtronic, Inc. Iontophoretic device with reversible polarity
US4820263A (en) * 1981-03-06 1989-04-11 Medtronic, Inc. Apparatus and method for iontophoretic drug delivery
JPS5810066A (ja) * 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4752285B1 (en) * 1986-03-19 1995-08-22 Univ Utah Res Found Methods and apparatus for iontophoresis application of medicaments
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
CA1317522C (en) * 1987-03-20 1993-05-11 Dan Sibalis Transdermal drug delivery system
AU615188B2 (en) * 1987-05-28 1991-09-26 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
FR2616333A1 (fr) * 1987-06-12 1988-12-16 Cird Procede d'ionophorese pour administrer une substance dissoute ou partiellement dissoute, par voie percutanee ou perungueale et dispositif correspondant
US4845233A (en) * 1987-09-11 1989-07-04 Iprx, Inc. Imidazolin-2-ones
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5057072A (en) * 1988-10-28 1991-10-15 Medtronic, Inc. Iontophoresis electrode
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US4950229A (en) * 1989-09-25 1990-08-21 Becton, Dickinson And Company Apparatus for an electrode used for iontophoresis
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5047007A (en) * 1989-12-22 1991-09-10 Medtronic, Inc. Method and apparatus for pulsed iontophoretic drug delivery
US5084008A (en) * 1989-12-22 1992-01-28 Medtronic, Inc. Iontophoresis electrode
US5084006A (en) * 1990-03-30 1992-01-28 Alza Corporation Iontopheretic delivery device
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles

Also Published As

Publication number Publication date
FI911267A (fi) 1991-09-16
EP0448300A2 (en) 1991-09-25
ZA911875B (en) 1992-03-25
ZA911876B (en) 1992-03-25
NO911020L (no) 1991-09-16
JPH06183999A (ja) 1994-07-05
KR910016317A (ko) 1991-11-05
AU7270091A (en) 1991-09-19
EP0448300A3 (en) 1991-12-27
US5334138A (en) 1994-08-02
JPH07103046B2 (ja) 1995-11-08
CA2038097C (en) 1997-01-07
KR910016316A (ko) 1991-11-05
FI911267A0 (fi) 1991-03-14
KR930005320B1 (ko) 1993-06-17
KR930005319B1 (ko) 1993-06-17
NO911020D0 (no) 1991-03-14
IE910714A1 (en) 1991-09-25
US5302172A (en) 1994-04-12
CA2038097A1 (en) 1991-09-16

Similar Documents

Publication Publication Date Title
KR910016318A (ko) 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물
KR900700153A (ko) 생리학적 활성물질 투여를 위한 폐색체
PT79182B (de) Mittel zur transdermalen applikation von arzneimittelwirkstoffen
DE3681570D1 (de) Medizinische einrichtung zur pulsatilen transdermalen verabreichung von biologisch aktiven wirkstoffen.
ES2053678T3 (es) Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
ES2035259T3 (es) Compuesto absorbente.
FI863990A (fi) Farmaseuttisen tai diagnostisen aineen oftalmologinen kantoainekoostumus
EP0164998A3 (en) Compositions and methods of enhancing transdermal and transmembrane penetration of topical and systemic agents
GB9409281D0 (en) Transdermal device
BE905928A (fr) Dispositif therapeutique pour administrer un agent actif sur la peau.
ATE65703T1 (de) Anordnung zur beseitigung von aktiven mitteln, oertlich verwendet gegen feste tumoren.
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
DE3575076D1 (de) Katheter fuer rueckinfusion von pharmazeutischen agenten.
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
SE8505047D0 (sv) Fettemulsion
DE3854631D1 (de) Pulsierendes transkutanes Arzneimittel-Abgabesystem.
ATE361772T1 (de) Behalter zur iontophoretischen verabreichung von medikamenten mit inerten material-bestandteilen
AT351666B (de) Einrichtung zur pflege von aerztlichen, insbesondere zahnaerztlichen handstuecken bzw. deren teilen
NL188891C (nl) Farmaceutisch preparaat met bloeddrukverlagende werking dat co-dergocrine en nog een actief materiaal bevat.
DE3877363D1 (de) Spritze.
TR200100020T2 (tr) Gliserol trinitrat içerikli bileşim, imalat yöntemleri ve kullanımı
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
KR900017599A (ko) 종양 치료용 약학 조성물
ATE97802T1 (de) Infusion sauerstoffreicher perfluorierter fluessigkeit im augapfel.

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition
O122 Withdrawal of opposition [patent]
E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970519

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee